EA033783B1 - Метаболически оптимизированная клеточная культура - Google Patents
Метаболически оптимизированная клеточная культура Download PDFInfo
- Publication number
- EA033783B1 EA033783B1 EA201690600A EA201690600A EA033783B1 EA 033783 B1 EA033783 B1 EA 033783B1 EA 201690600 A EA201690600 A EA 201690600A EA 201690600 A EA201690600 A EA 201690600A EA 033783 B1 EA033783 B1 EA 033783B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- cell culture
- cell
- lactate
- culture
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 184
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 133
- 230000002503 metabolic effect Effects 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
- 229920001184 polypeptide Polymers 0.000 claims abstract description 59
- 238000004519 manufacturing process Methods 0.000 claims abstract description 58
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 285
- 230000014509 gene expression Effects 0.000 claims description 36
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 230000003698 anagen phase Effects 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 11
- 239000006143 cell culture medium Substances 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 108091000831 antigen binding proteins Proteins 0.000 claims description 7
- 102000025171 antigen binding proteins Human genes 0.000 claims description 7
- 239000002054 inoculum Substances 0.000 claims description 7
- 230000005526 G1 to G0 transition Effects 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 103
- 102000004169 proteins and genes Human genes 0.000 abstract description 67
- 238000009825 accumulation Methods 0.000 abstract description 22
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000002699 waste material Substances 0.000 abstract description 5
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 64
- 230000010261 cell growth Effects 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 230000012010 growth Effects 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 108010091086 Recombinases Proteins 0.000 description 9
- 102000018120 Recombinases Human genes 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 238000011218 seed culture Methods 0.000 description 8
- 230000019522 cellular metabolic process Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 108010034634 Repressor Proteins Proteins 0.000 description 6
- 102000009661 Repressor Proteins Human genes 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 101150024821 tetO gene Proteins 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 235000020938 metabolic status Nutrition 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 102100037935 Polyubiquitin-C Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010056354 Ubiquitin C Proteins 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 230000001431 metabolomic effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229940066779 peptones Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 108091005941 EBFP Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 229940098695 palmitic acid Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 101150015970 tetM gene Proteins 0.000 description 2
- 101150061166 tetR gene Proteins 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 101100394813 Bacillus subtilis (strain 168) hprT gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100064677 Homo sapiens EDEM2 gene Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100030550 Nocardia iowensis npt gene Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000701835 Salmonella virus P22 Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 101150073130 ampR gene Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 101150047832 hpt gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- -1 such as an antibody Proteins 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 101150006320 trpR gene Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889815P | 2013-10-11 | 2013-10-11 | |
| PCT/US2014/059993 WO2015054554A1 (en) | 2013-10-11 | 2014-10-10 | Metabolically optimized cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690600A1 EA201690600A1 (ru) | 2016-09-30 |
| EA033783B1 true EA033783B1 (ru) | 2019-11-25 |
Family
ID=52813657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690600A EA033783B1 (ru) | 2013-10-11 | 2014-10-10 | Метаболически оптимизированная клеточная культура |
| EA201991976A EA201991976A1 (ru) | 2013-10-11 | 2014-10-10 | Метаболически оптимизированная клеточная культура |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991976A EA201991976A1 (ru) | 2013-10-11 | 2014-10-10 | Метаболически оптимизированная клеточная культура |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160244725A1 (enExample) |
| EP (3) | EP3351620B1 (enExample) |
| JP (3) | JP6663854B2 (enExample) |
| KR (4) | KR102358807B1 (enExample) |
| CN (2) | CN114717196A (enExample) |
| AU (2) | AU2014331776B2 (enExample) |
| CA (1) | CA2926049C (enExample) |
| DK (2) | DK3055409T3 (enExample) |
| EA (2) | EA033783B1 (enExample) |
| ES (2) | ES2833471T3 (enExample) |
| HU (2) | HUE051049T2 (enExample) |
| IL (2) | IL244511A0 (enExample) |
| MX (2) | MX376623B (enExample) |
| PL (2) | PL3055409T3 (enExample) |
| SG (2) | SG10201800772TA (enExample) |
| WO (1) | WO2015054554A1 (enExample) |
| ZA (1) | ZA201601550B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2833471T3 (es) | 2013-10-11 | 2021-06-15 | Regeneron Pharma | Cultivo celular metabólicamente optimizado |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| US20160244726A1 (en) * | 2013-10-11 | 2016-08-25 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| JP7260018B2 (ja) * | 2017-03-31 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7260011B2 (ja) * | 2017-03-31 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7260020B2 (ja) * | 2017-03-31 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7310947B2 (ja) * | 2017-04-27 | 2023-07-19 | 株式会社三洋物産 | 遊技機 |
| JP7272480B2 (ja) * | 2017-04-27 | 2023-05-12 | 株式会社三洋物産 | 遊技機 |
| JP7310952B2 (ja) * | 2017-04-27 | 2023-07-19 | 株式会社三洋物産 | 遊技機 |
| JP7260021B2 (ja) * | 2017-04-27 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7310945B2 (ja) * | 2017-04-27 | 2023-07-19 | 株式会社三洋物産 | 遊技機 |
| JP7260009B2 (ja) * | 2017-04-27 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7260012B2 (ja) * | 2017-04-27 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7260013B2 (ja) * | 2017-04-27 | 2023-04-18 | 株式会社三洋物産 | 遊技機 |
| JP7323512B2 (ja) | 2017-10-06 | 2023-08-08 | ロンザ リミテッド | ラマン分光法を使用する細胞培養の自動制御 |
| EP4039786A1 (en) | 2017-10-16 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Perfusion bioreactor and related methods of use |
| EP3717656B1 (en) * | 2017-11-30 | 2024-03-13 | F. Hoffmann-La Roche AG | Process for culturing mammalian cells |
| MX2020010028A (es) * | 2018-03-29 | 2020-10-14 | Genentech Inc | Actividad lactogenica modulada en celulas de mamifero. |
| GB201810772D0 (en) * | 2018-06-29 | 2018-08-15 | Ge Healthcare Bio Sciences Ab | Method in bioprocess purification system |
| JP7231355B2 (ja) * | 2018-08-22 | 2023-03-01 | 日機装株式会社 | 細胞培養方法および細胞培養装置 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| JP2020151559A (ja) * | 2020-06-24 | 2020-09-24 | 株式会社三洋物産 | 遊技機 |
| JP2020151560A (ja) * | 2020-06-24 | 2020-09-24 | 株式会社三洋物産 | 遊技機 |
| EP3985097A1 (en) * | 2020-10-14 | 2022-04-20 | Sartorius Stedim Biotech GmbH | A method and system for configuring and/or setup of a downstream process for processing a biomass |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6165741A (en) | 1997-05-30 | 2000-12-26 | The Trustees Of The University Of Pennsylvania | Method for rapid detection of bacterial growth in cultures |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6919183B2 (en) | 2001-01-16 | 2005-07-19 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US6953692B2 (en) * | 2001-12-18 | 2005-10-11 | Bayer Pharmaceuticals Corporation | Device and method for seed-train expansion of mammalian cells |
| US7039770B1 (en) | 2002-03-05 | 2006-05-02 | Juniper Networks, Inc. | Low latency request dispatcher |
| CA2417689C (en) | 2002-03-05 | 2006-05-09 | F. Hoffmann-La Roche Ag | Improved methods for growing mammalian cells in vitro |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| SI1623019T1 (sl) | 2003-05-15 | 2010-10-29 | Wyeth Llc | Omejeno glukozno dovajanje za živalsko celično kulturo |
| US7531327B2 (en) * | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| CA2628340A1 (en) * | 2005-11-02 | 2007-05-18 | Wyeth | Methods for adapting mammalian cells |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US7575890B2 (en) | 2006-01-18 | 2009-08-18 | Oxygen Enterprises, Ltd. | Method for rapid detection and evaluation of cultured cell growth |
| CA2666317C (en) | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| EP3327132A3 (en) | 2007-08-09 | 2018-07-18 | Wyeth LLC | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| SI2331678T1 (sl) * | 2008-06-13 | 2015-12-31 | Janssen Biotech, Inc. | Postopki za dobivanje visoke gostote viabilnih celic v sesalski celični kulturi |
| ES2533074T3 (es) * | 2010-04-26 | 2015-04-07 | Novartis Ag | Medio de cultivo celular mejorado |
| RU2614125C2 (ru) * | 2010-05-28 | 2017-03-22 | Дженентек, Инк. | Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы |
| TWI637057B (zh) | 2012-11-09 | 2018-10-01 | 拜爾沙納有限公司 | 具交替生物反應器用途之不連續進料批次製程 |
| WO2014109858A1 (en) * | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| ES2833471T3 (es) | 2013-10-11 | 2021-06-15 | Regeneron Pharma | Cultivo celular metabólicamente optimizado |
-
2014
- 2014-10-10 ES ES18161278T patent/ES2833471T3/es active Active
- 2014-10-10 MX MX2016004564A patent/MX376623B/es active IP Right Grant
- 2014-10-10 PL PL14851841T patent/PL3055409T3/pl unknown
- 2014-10-10 MX MX2020011334A patent/MX384960B/es unknown
- 2014-10-10 DK DK14851841.8T patent/DK3055409T3/en active
- 2014-10-10 EA EA201690600A patent/EA033783B1/ru active IP Right Revival
- 2014-10-10 KR KR1020217011547A patent/KR102358807B1/ko active Active
- 2014-10-10 KR KR1020237008467A patent/KR102610425B1/ko active Active
- 2014-10-10 CN CN202210497778.2A patent/CN114717196A/zh active Pending
- 2014-10-10 EP EP18161278.9A patent/EP3351620B1/en not_active Revoked
- 2014-10-10 EA EA201991976A patent/EA201991976A1/ru unknown
- 2014-10-10 ES ES14851841.8T patent/ES2678945T3/es active Active
- 2014-10-10 SG SG10201800772TA patent/SG10201800772TA/en unknown
- 2014-10-10 US US15/028,521 patent/US20160244725A1/en not_active Abandoned
- 2014-10-10 AU AU2014331776A patent/AU2014331776B2/en active Active
- 2014-10-10 KR KR1020167009163A patent/KR102243980B1/ko active Active
- 2014-10-10 CN CN201480055499.4A patent/CN105637085A/zh active Pending
- 2014-10-10 SG SG11201601681QA patent/SG11201601681QA/en unknown
- 2014-10-10 WO PCT/US2014/059993 patent/WO2015054554A1/en not_active Ceased
- 2014-10-10 PL PL18161278T patent/PL3351620T3/pl unknown
- 2014-10-10 EP EP14851841.8A patent/EP3055409B1/en not_active Revoked
- 2014-10-10 KR KR1020227003381A patent/KR102510238B1/ko active Active
- 2014-10-10 CA CA2926049A patent/CA2926049C/en active Active
- 2014-10-10 DK DK18161278.9T patent/DK3351620T3/da active
- 2014-10-10 EP EP20193898.2A patent/EP3812453A1/en active Pending
- 2014-10-10 JP JP2016547976A patent/JP6663854B2/ja active Active
- 2014-10-10 HU HUE18161278A patent/HUE051049T2/hu unknown
- 2014-10-10 HU HUE14851841A patent/HUE039551T2/hu unknown
-
2016
- 2016-03-04 ZA ZA2016/01550A patent/ZA201601550B/en unknown
- 2016-03-08 IL IL244511A patent/IL244511A0/en unknown
-
2018
- 2018-11-06 IL IL262833A patent/IL262833A/en unknown
-
2020
- 2020-02-17 JP JP2020024484A patent/JP6967620B2/ja active Active
- 2020-08-04 US US16/984,531 patent/US20210087535A1/en active Pending
-
2021
- 2021-01-14 AU AU2021200193A patent/AU2021200193B2/en active Active
- 2021-10-25 JP JP2021173755A patent/JP7377243B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
Non-Patent Citations (3)
| Title |
|---|
| LE H. et al.: "Multivariate analysis of cell culture bioprocess data - lactate consumption as process indicator", Journal of Biotechnology, 2012, vol. 162, pages 210-223, abstract; page 211, paragraphs 3 and 4; page 214, paragraph 4; page 218, paragraph 6 to page 221, paragraph 2; page 222, paragraphs 3-5; figure 2D and 9 * |
| MA N. et al.: "A single nutrient feed supports both chemically defined NS0 and CHO fed-batch processes: improved productivity and lactate metabolism", Biotechnology Progress, 2009, vol. 25, No. 5, pages 1353-1363, abstract; page 1356, paragraph 5 to page 358, paragraph 2; figures 2-4 * |
| SHEIKHOLESLAMI Z. et al.: "The impact of the timing of induction on the metabolism and productivity of CHO cells in culture", Biochemical Engineering Journal, 2013, vol. 79, pages 162-171; published online on 08 August 2013, abstract; figure 1, page 168, paragraph 3, page 169, paragraph 4 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200193B2 (en) | Metabolically optimized cell culture | |
| US20250326820A1 (en) | Metabolically optimized cell culture | |
| US20160244726A1 (en) | Metabolically optimized cell culture | |
| HK40042432A (en) | Metabolically optimized cell culture | |
| HK1253275B (en) | Metabolically optimized cell culture | |
| EA040764B1 (ru) | Метаболически оптимизированная клеточная культура | |
| EA045030B1 (ru) | Метаболически оптимизированная клеточная культура | |
| HK1223122B (en) | Metabolically optimized cell culture | |
| BR122024020669A2 (pt) | Método para cultivar células, e, célula hospedeira metabolicamente alterada | |
| BR122024020665A2 (pt) | Método para cultivar células, e, célula hospedeira metabolicamente alterada | |
| BR112016007739B1 (pt) | Método para cultivar células |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |
|
| NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AM AZ BY KZ KG TJ TM RU |